

IAPG Rec'd PCT/PTO 28 FEB 2006

AC/SAS:gth 02/28/06 4239-66649-03 491969 E-323-2003/0-US-03


EXPRESS MAIL LABEL NO. EV669611737US
DATE OF DEPOSIT: February 28, 2006

Applicants filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. Deposit Account authority is provided on the accompanying transmittal letter.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 

Anne Carlson, Ph.D.
Registration No. 47,472

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	4239-66649-03
Application Number	20030220
Filing Date	Herewith
First Named Inventor	Kashmiri
Art Unit	
Examiner Name	

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		4,816,567	28 March 1989	Cabilly <i>et al.</i>
		5,472,693	5 Dec 1995	Gourlie <i>et al.</i>
		5,482,040	9 Jan 1996	Martin, Jr.
		5,512,443	30 April 1996	Schlom <i>et al.</i>
		5,534,254	9 July 1996	Huston <i>et al.</i>
		5,585,089	17 Dec 1996	Queen <i>et al.</i>
		5,688,657	18 Nov 1997	Tsang <i>et al.</i>
		5,976,531	2 Nov 1999	Mezes <i>et al.</i>
		5,976,845	2 Nov 1999	Mezes <i>et al.</i>
		5,994,511	30 Nov 1999	Lowman <i>et al.</i>
		6,054,297	25 April 2000	Carter <i>et al.</i>
		6,180,370	30 Jan 2001	Queen <i>et al.</i>
		6,333,405	25 Dec 2001	Anderson <i>et al.</i>
		6,495,137	17 Dec 2002	Mezes <i>et al.</i>

EXAMINER
SIGNATURE:DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

28 FEB 2006

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	4239-66649-03
	Application Number	
	Filing Date	Herewith
	First Named Inventor	Kashmiri
	Art Unit	
	Examiner Name	

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		Canada	2,068,593 ✓	8 July 2003	Mark <i>et al.</i>
		Canada	2,131,355 ✓	2 March 1996	Shu <i>et al.</i>
		EPC	EP0239400	30 Sep 1987	Winter, G.
		EPC	EP0365997	2 May 1990	Mezes <i>et al.</i>
		WIPO/PCT	WO 89/00692	26 Jan 1989	Schlom <i>et al.</i>
		WIPO/PCT	WO 89/01783	9 March 1989	Bodmer <i>et al.</i>
		WIPO/PCT	WO 90/04410	3 May 1990	Mezes <i>et al.</i>
		WIPO/PCT	WO 91/00295	10 Jan 1991	Hellstrom <i>et al.</i>
		WIPO/PCT	WO 93/12231	24 June 1993	Mezes <i>et al.</i>
		WIPO/PCT	WO 96/13594 ✓	9 May 1996	Pastan <i>et al.</i>
		WIPO/PCT	WO 97/26010 ✓	24 July 1997	Blackburn <i>et al.</i>
		WIPO/PCT	WO 98/18809 ✓	7 May 1998	Greenburg <i>et al.</i>
		WIPO/PCT	WO 99/43816 ✓	2 Sep 1999	Anderson <i>et al.</i>
		WIPO/PCT	WO 00/26394 ✓	11 May 2000	Kashmiri <i>et al.</i>
		WIPO/PCT	WO 04/003155 ✓	8 January 2004	Kashmiri <i>et al.</i>

EXAMINER SIGNATURE:	DATE CONSIDERED:
---------------------	------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

2006

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	4239-66649-03
	Application Number	92/570220
	Filing Date	Herewith
	First Named Inventor	Kashmiri
	Art Unit	
	Examiner Name	

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
		ABERGEL <i>et al.</i> , "Crystallographic Studies and Primary Structure of the Antitumor Monoclonal CC49 Fab'," <i>Proteins: Structure, Function, and Genetics</i> 17:438-443, 1993.
		BERZOFISKY <i>et al.</i> , p. 242, <i>Fundamental Immunology</i> , Paul (Ed.) Raven Press, NY, 1993
		COLCHER <i>et al.</i> , "Radioimmunolocalization of Human Carcinoma Xenografts with B72.3 Second Generation Monoclonal Antibodies," <i>Cancer Research</i> 48:4597-4603, 1988.
		De PASCALIS <i>et al.</i> , "Generation of minimally immunogenic high affinity variants of humanized anti-carcinoma antibody HuCC49V10 by in vitro affinity maturation," <i>Proceedings of the American Association for Cancer Research</i> , 44(2):1115-1116, 2003.
		De PASCALIS <i>et al.</i> , "In Vitro Affinity Maturation of a Specificity-Determining Region-Grafted Humanized Anticarcinoma Antibody: Isolation and Characterization of Minimally Immunogenic High-Affinity Variants," <i>Clinical Cancer Research</i> , 9:5521-5531, 2003.
		DIVGI <i>et al.</i> , "Clinical Comparison of Radiolocalization of Two Monoclonal Antibodies (mAbs) Against the TAG-72 Antigen," <i>Nucl. Med. Biol.</i> 21(1):9-15, 1994.
		GONZALES <i>et al.</i> , "Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues," <i>Molecular Immunology</i> , 40(6):337-349, 2003.
		GONZALES <i>et al.</i> , "Reducing the potential immunogenicity of humanized CC49 by genetic manipulation of framework residues," <i>Proceedings of the American Association for Cancer Research</i> , 44:1118, 2003.
		HAKIMI <i>et al.</i> , "Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys," <i>J. Immunol.</i> 147:1352-1359, 1991.
		HAND <i>et al.</i> , "Potential for Recombinant Immunoglobulin Constructs in the Management of Carcinoma," <i>Cancer Supplement</i> 73(3):1105-1113, 1994.
		IWAHASHI <i>et al.</i> , "CDR Substitutions of a Humanized Monoclonal Antibody (CC49): Contributions of Individual CDRs to Antigen Binding and Immunogenicity," <i>Molecular Immunology</i> 36:1079-1091, 1999.
		JOHNSON <i>et al.</i> , "Analysis of a Human Tumor-associated Glycoprotein (TAG-72) Identified by Monoclonal Antibody B72.3," <i>Cancer Research</i> 46:850-857, 1986.
		JONES <i>et al.</i> , "Replacing the Complementarity-determining Regions in a Human Antibody with those from a Mouse," <i>Nature</i> 321:522-525, 1986.

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	4239-66649-03
	Application Number	
	Filing Date	Herewith 02/28/06
	First Named Inventor	Kashmiri
	Art Unit	
	Examiner Name	

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
		KASHMIRI <i>et al.</i> , Chapter 21 in <i>Methods in Molecular Biology, Vol. 248: Antibody Engineering: Methods and Protocols</i> , p. 361-376; Lo (ed.), Humana Press, Inc., Tolowa, NJ, 2003
		KASHMIRI <i>et al.</i> , "Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49," <i>Crit. Rev. Oncol. Hematol.</i> 38:3-16, 2001.
		KASHMIRI <i>et al.</i> , "Generation, Characterization, and <i>in Vivo</i> Studies of Humanized Anticarcinoma Antibody CC49," <i>Hybridoma</i> 14(5):461-473, 1995.
		KASHMIRI <i>et al.</i> , "SDR grafting – a new approach to antibody humanization," <i>Methods</i> , 36:25-34, 2005
		MULLIGAN <i>et al.</i> , "Phase I Study of Intravenous ¹⁷⁷ Lu-labeled CC49 Murine Monoclonal Antibody in Patients with Advanced Adenocarcinoma," <i>Clinical Cancer Research</i> 1:1447-1454, 1995.
		MURARO <i>et al.</i> , "Generation and Characterization of B72.3 Second Generation Monoclonal Antibodies Reactive with the Tumor-associated Glycoprotein 72 Antigen," <i>Cancer Research</i> 48:4588-4596, 1988.
		PADLAN, "A Possible Procedure for Reducing the Immunogenicity of Antibody Variable Domains while Preserving their Ligand-binding Properties," <i>Molecular Immunology</i> 28(4/5):489-498, 1991.
		PADLAN, "Anatomy of the antibody molecule," <i>Mol. Immunol.</i> 31:169-217, 1994.
		PADLAN <i>et al.</i> , "Identification of Specificity-determining Residues in Antibodies," <i>The FASEB Journal</i> 9:133-139, 1995.
		RIECHMAN <i>et al.</i> , "Reshaping human antibodies for therapy," <i>Nature (London)</i> 332:323-327, 1988.
		RIXON <i>et al.</i> , "Preferential Use of a H Chain V Region in Antitumor-associated Glycoprotein-72 Monoclonal Antibodies," <i>The Journal of Immunology</i> 151(11):6559-6568, 1993.
		RUDIKOFF <i>et al.</i> , "Single amino acid substitution altering antigen-binding specificity," <i>PNAS</i> 79(6):1979-1983, 1982
		SALDANHA <i>et al.</i> , "A single backmutation in the human kIV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells," <i>Mol. Immunol.</i> 36:709-719, 1999.

EXAMINER SIGNATURE:	DATE CONSIDERED:
------------------------	---------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	4239-66649-03
	Application Number	4239-220
	Filing Date	Herewith
	First Named Inventor	Kashmiri
	Art Unit	
	Examiner Name	

	SCHIER <i>et al.</i> , "Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site," <i>J. Mol. Biol.</i> 263:551-567, 1996.
	SHA <i>et al.</i> , "A Heavy-chain Grafted Antibody that Recognizes the Tumor-associated TAG72 Antigen," <i>Cancer Biotherapy</i> 9(4):341-349, 1994.
	SHARKEY <i>et al.</i> , "Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies," <i>Cancer Res.</i> 55:5935s-5945s, 1995.
	SLAVIN-CHIORINI <i>et al.</i> , "A CDR-grafted (humanized) domain-deleted antitumor antibody," <i>Cancer Biother. Radiopharm.</i> 12:305-316, 1997.
	SLAVIN-CHIORINI <i>et al.</i> , "Biological Properties of Chimeric Domain-deleted Anticarcinoma Immunoglobulins," <i>Cancer Research (Supplement)</i> 55:5957s-5967s, 1995.
	TAMURA <i>et al.</i> , "Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only," <i>Journal of Immunology</i> 164(3):1432-1441, 2000.
	WU <i>et al.</i> , "Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues," <i>J. Mol. Biol.</i> 294:151-162, 1999.
	XIANG <i>et al.</i> , "The Tyrosine Residue at Position 97 in the V _H CDR3 Region of a Mouse/Human Chimeric Anti-Colorectal Carcinoma Antibody Contributes Hydrogen Bonding to the TAG72 Antigen," <i>Cancer Biotherapy</i> 8(3):253-262, 1993.
	XIANG <i>et al.</i> , "Complementarity Determining Region Residues Aspartic Acid at H55, Serine at H95 and Tyrosines at H97 and L96 Play Important Roles in the B72.3 Antibody-TAG72 Antigen Interaction," <i>Protein Engineering</i> 9(6):539-543, 1996.
	XIANG <i>et al.</i> , "Light-chain framework region residue Tyr71 of chimeric B72.3 antibody plays an important role in influencing the TAG72 antigen binding," <i>Protein Eng.</i> 12:417-421, 1999.
	International Search Report issued on April 15, 2005, for PCT Patent Application No. PCT/US2004/028004.

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	